SCHEMBL1462152

SCHEMBL1462152

CN[C@@H](C)C(=O)N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6008958 1.00
SCHEMBL1462155 1.00
Hydrochloric Acid SCHEMBL1465292 0.97 ALDH1A1 (0.30)
Hydrochloric Acid SCHEMBL1465289 0.97 ALDH1A1 (0.30)
Trifluoroacetic Acid SCHEMBL2499956 0.85 DPP4 (0.32)
SCHEMBL22814569 0.78
SCHEMBL15727234 0.76
SCHEMBL794067 0.76
SCHEMBL15387030 0.76
SCHEMBL14365720 0.75 JAK2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194536-A1 Cyanoarylamines SMITHKLINE BEECHAM CORPORATION 2008-08-14 US claimed
EP-4269422-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-01 EP disclosed
EP-4218826-A2 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS Mersana Therapeutics, Inc. (US) 2023-08-02 EP disclosed
US-11492369-B2 Method for producing peptide, and method for processing bases CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-11-08 US disclosed
US-9481670-B2 Triazine compounds SPHAERA PHARMA PTE. LTD. (SG) 2016-11-01 US disclosed
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS SPHAERA PHARMA PTE. LTD. (SG) 2013-11-14 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20110172422-A1 Methods of Making Pharmacokinetically Improved Compounds Comprising Functional Residues or Groups and Pharmaceutical Compositions Comprising Said Compounds SURFACE LOGIX, INC. (US) 2011-07-14 US disclosed
US-20110172422-A1 Methods of Making Pharmacokinetically Improved Compounds Comprising Functional Residues or Groups and Pharmaceutical Compositions Comprising Said Compounds SURFACE LOGIX, INC. (US) 2011-07-14 US disclosed
US-20110071132-A1 SUBSTITUTED OXINDOLE DERIVATIVES, DRUGS CONTAINING SAID DERIVATIVES AND THE USE THEREOF ABBOTT GMBH & CO. KG (DE) 2011-03-24 US disclosed
US-20090163492-A1 Substituted Oxindole Derivatives, Drugs Containing Said Derivatives and the Use Thereof ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-06-25 US disclosed
US-20090163492-A1 Substituted Oxindole Derivatives, Drugs Containing Said Derivatives and the Use Thereof ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-06-25 US disclosed
US-20080176844-A1 Pharmacokinetically Improved Compounds SURFACE LOGIX, INC. 2008-07-24 US disclosed
US-20080176844-A1 Pharmacokinetically Improved Compounds SURFACE LOGIX, INC. 2008-07-24 US disclosed
US-20080176844-A1 Pharmacokinetically Improved Compounds SURFACE LOGIX, INC. 2008-07-24 US disclosed
EP-1871379-A2 CYANOARYLAMINES Smithkline Beecham Corporation (US) 2008-01-02 EP disclosed
EP-1848437-A2 METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS Surface Logix, Inc. (US) 2007-10-31 EP disclosed
WO-2006113552-A2 CYANOARYLAMINES SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 WO disclosed
WO-2006089275-A2 METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS SURFACE LOGIX, INC. (US) 2006-08-24 WO disclosed
WO-2006089275-A2 METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS SURFACE LOGIX, INC. (US) 2006-08-24 WO disclosed